These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

167 related items for PubMed ID: 20580393

  • 1. Design and evaluation of antiretroviral peptides corresponding to the C-terminal heptad repeat region (C-HR) of human immunodeficiency virus type 1 envelope glycoprotein gp41.
    Soonthornsata B, Tian YS, Utachee P, Sapsutthipas S, Isarangkura-na-Ayuthaya P, Auwanit W, Takagi T, Ikuta K, Sawanpanyalert P, Kawashita N, Kameoka M.
    Virology; 2010 Sep 15; 405(1):157-64. PubMed ID: 20580393
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Differential inhibition of HIV-1 and SIV envelope-mediated cell fusion by C34 peptides derived from the C-terminal heptad repeat of gp41 from diverse strains of HIV-1, HIV-2, and SIV.
    Gustchina E, Hummer G, Bewley CA, Clore GM.
    J Med Chem; 2005 Apr 21; 48(8):3036-44. PubMed ID: 15828842
    [Abstract] [Full Text] [Related]

  • 4. Characterization of HIV-1 resistance to a fusion inhibitor, N36, derived from the gp41 amino-terminal heptad repeat.
    Izumi K, Nakamura S, Nakano H, Shimura K, Sakagami Y, Oishi S, Uchiyama S, Ohkubo T, Kobayashi Y, Fujii N, Matsuoka M, Kodama EN.
    Antiviral Res; 2010 Aug 21; 87(2):179-86. PubMed ID: 20438763
    [Abstract] [Full Text] [Related]

  • 5. Mutations conferring resistance to human immunodeficiency virus type 1 fusion inhibitors are restricted by gp41 and Rev-responsive element functions.
    Nameki D, Kodama E, Ikeuchi M, Mabuchi N, Otaka A, Tamamura H, Ohno M, Fujii N, Matsuoka M.
    J Virol; 2005 Jan 21; 79(2):764-70. PubMed ID: 15613304
    [Abstract] [Full Text] [Related]

  • 6. Stronger anti-HIV-1 activity of C-peptide derived from HIV-1 89.6 gp41 C-terminal heptad repeated sequence.
    Seo JK, Kim HK, Lee TY, Hahm KS, Kim KL, Lee MK.
    Peptides; 2005 Nov 21; 26(11):2175-81. PubMed ID: 15876473
    [Abstract] [Full Text] [Related]

  • 7. Different susceptibility of human immunodeficiency virus type 1 to Env gp41-derived synthetic peptides corresponding to the C-terminal heptad repeat region.
    N A PI, Li GM, Warachit J, Iwabu Y, Tsuji S, Auwanit W, Yamamoto D, Goto T, Hayashi Y, Kiso Y, Ikuta K.
    Microbes Infect; 2005 Mar 21; 7(3):356-64. PubMed ID: 15780966
    [Abstract] [Full Text] [Related]

  • 8. Retrocyclin RC-101 overcomes cationic mutations on the heptad repeat 2 region of HIV-1 gp41.
    Fuhrman CA, Warren AD, Waring AJ, Dutz SM, Sharma S, Lehrer RI, Cole AL, Cole AM.
    FEBS J; 2007 Dec 21; 274(24):6477-87. PubMed ID: 18028423
    [Abstract] [Full Text] [Related]

  • 9. Electrostatically constrained alpha-helical peptide inhibits replication of HIV-1 resistant to enfuvirtide.
    Nishikawa H, Nakamura S, Kodama E, Ito S, Kajiwara K, Izumi K, Sakagami Y, Oishi S, Ohkubo T, Kobayashi Y, Otaka A, Fujii N, Matsuoka M.
    Int J Biochem Cell Biol; 2009 Apr 21; 41(4):891-9. PubMed ID: 18834950
    [Abstract] [Full Text] [Related]

  • 10. X-ray crystallographic study of an HIV-1 fusion inhibitor with the gp41 S138A substitution.
    Watabe T, Terakawa Y, Watanabe K, Ohno H, Nakano H, Nakatsu T, Kato H, Izumi K, Kodama E, Matsuoka M, Kitaura K, Oishi S, Fujii N.
    J Mol Biol; 2009 Sep 25; 392(3):657-65. PubMed ID: 19616557
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Protein design of a bacterially expressed HIV-1 gp41 fusion inhibitor.
    Deng Y, Zheng Q, Ketas TJ, Moore JP, Lu M.
    Biochemistry; 2007 Apr 10; 46(14):4360-9. PubMed ID: 17371053
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Human immunodeficiency virus (HIV) gp41 escape mutants: cross-resistance to peptide inhibitors of HIV fusion and altered receptor activation of gp120.
    Desmezieres E, Gupta N, Vassell R, He Y, Peden K, Sirota L, Yang Z, Wingfield P, Weiss CD.
    J Virol; 2005 Apr 10; 79(8):4774-81. PubMed ID: 15795263
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Functional and structural characterization of HIV-1 gp41 ectodomain regions in phospholipid membranes suggests that the fusion-active conformation is extended.
    Korazim O, Sackett K, Shai Y.
    J Mol Biol; 2006 Dec 15; 364(5):1103-17. PubMed ID: 17045292
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Hydrophobic mutations in buried polar residues enhance HIV-1 gp41 N-terminal heptad repeat-C-terminal heptad repeat interactions and C-peptides' anti-HIV activity.
    Zheng B, Wang K, Lu L, Yu F, Cheng M, Jiang S, Liu K, Cai L.
    AIDS; 2014 Jun 01; 28(9):1251-60. PubMed ID: 24625369
    [Abstract] [Full Text] [Related]

  • 19. The C34 Peptide Fusion Inhibitor Binds to the Six-Helix Bundle Core Domain of HIV-1 gp41 by Displacement of the C-Terminal Helical Repeat Region.
    Louis JM, Baber JL, Clore GM.
    Biochemistry; 2015 Nov 17; 54(45):6796-805. PubMed ID: 26506247
    [Abstract] [Full Text] [Related]

  • 20. The hydrophobic pocket contributes to the structural stability of the N-terminal coiled coil of HIV gp41 but is not required for six-helix bundle formation.
    Dwyer JJ, Hasan A, Wilson KL, White JM, Matthews TJ, Delmedico MK.
    Biochemistry; 2003 May 06; 42(17):4945-53. PubMed ID: 12718536
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.